Drug Profile
Dolutegravir/rilpivirine - Janssen/ViiV Healthcare
Alternative Names: Dolutegravir sodium/rilpivirine hydrochloride; Juluca; Rilpivirine hydrochloride/dolutegravir sodium; Rilpivirine/dolutegravirLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Janssen Research & Development; ViiV Healthcare
- Class 3-ring heterocyclic compounds; Amides; Antiretrovirals; Benzonitrile; Nitriles; Oxazines; Pyrimidines; Small molecules
- Mechanism of Action HIV integrase inhibitors; Non-nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed HIV infections
Most Recent Events
- 30 May 2023 ViiV Healthcare completes the phase III SWORD-1 trial for HIV infections (Treatment-experienced) in USA, Argentina, Australia, Belgium, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, Taiwan, the UK (PO) (NCT02429791)
- 25 May 2023 ViiV Healthcare completes the phase III SWORD-2 trial for HIV infections (Treatment-experienced) in the US, the UK, Argentina, Taiwan, Australia, Canada, France, Germany, Italy, Russia, and Spain (PO) (NCT reference) (NCT02422797)
- 06 Jan 2023 ViiV Healthcare in a collaboration with Janssen Research & Development plans a phase I/II trial in HIV-1 infections (Treatment-experienced, In children) in February 2023 (NCT05674656)